Anti-inflammatory intestinal activity of Combretum duarteanum Cambess. in trinitrobenzene sulfonic acid colitis model.

about

Anti-inflammatory intestinal activity of Combretum duarteanum Cambess. in trinitrobenzene sulfonic acid colitis model.

Item

http://www.wikidata.org/entity/Q38908245

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Anti-inflammatory intestinal a ...... e sulfonic acid colitis model.

@en

type

Item

label

Anti-inflammatory intestinal a ...... e sulfonic acid colitis model.

@en

prefLabel

Anti-inflammatory intestinal a ...... e sulfonic acid colitis model.

@en

P1476

Anti-inflammatory intestinal a ...... ne sulfonic acid colitis model

@en

P2093

Alba Regina Monteiro Souza Brito

http://www.w3.org/2001/XMLSchema#string

Anderson Luiz-Ferreira

http://www.w3.org/2001/XMLSchema#string

Flavia Danniele Frota Machado

http://www.w3.org/2001/XMLSchema#string

Gedson Rodrigues de Morais Lima

http://www.w3.org/2001/XMLSchema#string

Larissa Lucena Périco

http://www.w3.org/2001/XMLSchema#string

Leônia Maria Batista

http://www.w3.org/2001/XMLSchema#string

P2860

Current trends in inflammatory bowel disease: the natural history

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Immunopathology of inflammatory bowel disease

Intestinal barrier function: molecular regulation and disease pathogenesis

Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock

The immunological and genetic basis of inflammatory bowel disease.

Clinical aspects and pathophysiology of inflammatory bowel disease.

Differential immune and genetic responses in rat models of Crohn's colitis and ulcerative colitis.

Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.

Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.

P304

1353-1366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V23.I8.1353

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

José Maria Barbosa Filho

Josean F Tavares

Clélia Akiko Hiruma-Lima

Felipe Meira de Faria

Claudia Helena Pellizzon

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28293082

http://www.w3.org/2001/XMLSchema#string

P932

5330820

http://www.w3.org/2001/XMLSchema#string